PS
PCVX icon

Planning Strategies’s Vaxcyte PCVX Stock Holding History

Planning Strategies’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$116 Buy
+2
New +$109 ﹤0.01% 1025

Other funds holding PCVX

JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Planning Strategies's PCVX Position: Q2 2026 in Review

Planning Strategies opened a new position in Vaxcyte (PCVX) in Q2 2026: 2 shares worth $116. The stake represents ﹤0.01% of the portfolio and ranks #1025 among its holdings.

307 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

  • Planning Strategies held 2 shares of Vaxcyte worth $116 as of Q2 2026.
  • Vaxcyte was a new Planning Strategies position in Q2 2026.
  • Vaxcyte made up ﹤0.01% of Planning Strategies's portfolio in Q2 2026, its #1025 holding.
  • 307 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on Planning Strategies's 13F filing for Q2 2026, filed 27 Jul 2026.